Results 61 to 70 of about 148,019 (190)
ABSTRACT Introduction Persons living with cystic fibrosis (PwCF) have experienced fewer exacerbations and symptom burden over the last decade, largely thanks to widespread uptake of highly effective modulator therapy (HEMT). With these advancements, there have been interest in the community regarding adjustments to the care model.
William R. Hunt +5 more
wiley +1 more source
ABSTRACT Background Severe and difficult to treat asthma in children is a complex condition causing significant morbidity and associated healthcare costs. While treatment guidelines exist for severe asthma, optimal treatment approaches for the pediatric population are less well established.
Kristina Gaietto +31 more
wiley +1 more source
Demographic and Comorbidity Associations With Disease Severity and Bony Dehiscence in AFRS
ABSTRACT Objective(s) The purpose of this study is to explore and describe possible demographic factors and comorbidities as they relate to disease severity of allergic fungal rhinosinusitis (AFRS) on initial presentation. Methods A retrospective review was conducted on 153 patients with AFRS seen at a tertiary care center. Demographics, comorbidities,
Diana Bigler +6 more
wiley +1 more source
Eosinophilic Pleural Effusion Complicating Allergic Bronchopulmonary Aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) is primarily a disease of patients with cystic fibrosis or asthma, who typically present with bronchial obstruction, fever, malaise, and expectoration of mucus plugs.
Tomasz J. Kuzniar +2 more
core +1 more source
In a case series from a hospital in North India, A. nidulans strains isolated from patients with pulmonary aspergillosis were phenotypically identified and then underwent molecular characterization through sequencing of the amplified ITS1‐5.8S rDNA‐ITS2 region and antifungal susceptibility testing (AST) according to the CLSI M38A3 guidelines.
Aishwarya Nikhil +8 more
wiley +1 more source
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
Moshe Ashkenazi,1,2 Saray Sity,2 Ifat Sarouk,1,2 Bat El Bar Aluma,1,2 Adi Dagan,1,2 Yael Bezalel,1,2 Lea Bentur3 Kris De Boeck,4 Ori Efrati1,2 1Pediatric Pulmonology and National CF Center,
Sarouk I +8 more
core
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang +3 more
wiley +1 more source
A Case for Anti‐IgE Vaccination
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff +3 more
wiley +1 more source
The diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis patients remains challenging, mainly owing to overlapping symptoms of the underlying lung disease with clinical symptoms of ABPA.
Nicolas Regamey +14 more
core +1 more source
A aspergilose broncopulmonar alérgica é uma doença pulmonar que ocorre em pacientes com asma ou fibrose cística, desencadeada pela reação de hipersensibilidade à presença do fungo Aspergilus fumigatus nas vias aéreas.
Marta Elizabeth Kalil +4 more
doaj +1 more source

